Austrian researchers report a breakthrough mpox infection in a fully vaccinated man who received two doses of the Jynneos vaccine. The case highlights the potential durability of protective immunity after complete vaccination and emphasizes the importance of clinical suspicion in high-risk groups.
Researchers found that Mpox antibodies decrease significantly within a year of MVA-BN vaccination, especially in individuals without prior smallpox vaccination. In contrast, antibody levels remained high in those with childhood smallpox vaccination, suggesting long-term protection.
A Swedish study reveals that neutralising antibodies to the monkeypox virus decline significantly after two doses of the MVA-BN vaccine within the first month. The findings suggest that a booster dose may be necessary to maintain immunity, emphasizing the need for scientific evidence before policy decisions are made.